Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588076 | 1.00 | HTR2A (0.42) | HTR2AHTR2CHTR2BCYP3A4MEN1 | |
| Hydrochloric Acid SCHEMBL550115 | 0.98 | HTR2C (0.41) | HTR2AHTR2CHTR2BCYP3A4MEN1 | |
| SCHEMBL9058489 | 0.80 | HTR2A (0.62) | HTR2AHTR2CHTR2BCYP3A4MEN1 | |
| SCHEMBL24124813 | 0.80 | CYP3A4 (0.38) | HTR2AHTR2CHTR2BCYP3A4MEN1 | |
| SCHEMBL6956152 | 0.80 | HTR2A (0.41) | HTR2AHTR2CCYP3A4MEN1CYP2D6 | |
| SCHEMBL24882652 | 0.77 | ALDH1A1 (0.44) | HTR2CCYP3A4MEN1CYP2D6ALOX15 | |
| SCHEMBL22445688 | 0.77 | SIGMAR1 (0.50) | HTR2AHTR2CHTR2BCYP3A4MEN1 | |
| SCHEMBL23981768 | 0.77 | KMT2A (0.41) | HTR2AHTR2CHTR2BCYP3A4MEN1 | |
| SCHEMBL23535520 | 0.75 | HTR2A (0.39) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL2256944 | 0.75 | HTR2A (0.43) | HTR2AHTR2CHTR2BDRD2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0501997-A1 | N-ACYL-SUBSTITUTED AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS. | ZAMBELETTI SPA L (IT) | 1992-09-09 | — | — | EP | claimed |
| US-20230350294-A1 | Negative Photosensitive Resin Composition, Patterning Process, Interlayer Insulating Film, Surface Protection Film, And Electronic Component | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-11768434-B2 | Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-26 | — | — | US | disclosed |
| US-11768434-B2 | Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-26 | — | — | US | disclosed |
| WO-2021030620-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020210381-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200041903-A1 | POLYMER HAVING A STRUCTURE OF POLYAMIDE, POLYAMIDE-IMIDE, OR POLYIMIDE, PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, PHOTOSENSITIVE DRY FILM, AND PROTECTIVE FILM FOR ELECTRIC AND ELECTRONIC PARTS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-2225223-B1 | ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2958918-B1 | DIHYDROPTERIDINONES II | BOEHRINGER INGELHEIM INT (DE) | 2016-12-07 | — | — | EP | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-6849644-B2 | Isoquinoline derivatives useful in the treatment of CNS disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-01 | — | — | US | disclosed |
| CN-1494542-A | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ������˹ҩƷ��˾ | 2004-05-05 | — | — | CN | disclosed |
| US-20040053956-A1 | Isoquinoline derivatives useful in the treatment of cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-18 | — | — | US | disclosed |
| EP-1341783-A1 | ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002042293-A1 | ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-30 | — | — | WO | disclosed |
| US-6358974-B1 | USED AS AS MODULATORS OF DOPAMINE D.SUB.3 RECEPTORS, IN THERAPY AS ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-19 | — | — | US | disclosed |
| EP-1137638-A2 | ISOQUINOLINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000024717-A2 | ISOQUINOLINE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053956-A1 | Isoquinoline derivatives useful in the treatment of cns disorders | INA, NLN, GRIN2C | HTR2A 104/4885HTR2C 75/4885HTR2B 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.